Future Healthcare 100 List Upgraded: 2024 VBEF Awards Call for Submissions!
Standing at the forefront amidst turbulent times, forging ahead with courage and determination.
In 2024, the Top 100 Future Healthcare Conference was comprehensively upgraded to the VBEF Future Healthcare Ecological Fair (2024 FUTURE HEALTHCARE ECOLOGICAL FAIR)），Centered on the needs of enterprises in the healthcare sector, and spanning the entire industry—including biopharmaceuticals, medical devices, digital health, healthcare services, and commercial healthcare and supply chain services—we focus on global innovations in the healthcare industry: new technologies, new models, new practices, and new ecosystems.The selection criteria for the Future Healthcare Top 100 list have also been adjusted, with a comprehensive upgrade toVCBeat Evaluation.
The 2024 VBEF Awards include the 2024 VBEF Rankings and the 2024 VBEF Innovation Award.
VBInsight Ranking（Original Future Healthcare 100 List), this year’s rankings comprise the Non-Listed Companies Rankings (Top 100 Innovative Medical Devices and Intelligent Manufacturing, Top 100 Innovative Pharmaceuticals and Biologics, Top 100 Digital Healthcare and Health Services, and Top 100 Healthcare Commerce and Supply Chain Services) and the Top 100 Listed Companies Innovation Rankings.
VBEF Innovation Award（Former Future Healthcare Top 100 Pengcheng Award, WeilanAward), this year's Innovation Awards are divided into five major categories based on the different entities being evaluated: Institutional Award, Enterprise Award, Industrial Park Award, Individual Award, and Product Award.
Starting today, submissions for the 2024 VBEF Rankings and Innovation Awards are now open. Additional award categories will be gradually unveiled from February to March 2024. All rankings and awards will be announced at the 2024 Future Healthcare Ecosystem Exhibition.
This ranking is targeted at non-listed companies in the healthcare and medical sector. The selection process is based on the VB100 value assessment model, proceeding through stages of self-declaration by enterprises, review by the VBEF Review Committee, cross-review by supporting institutions, and final adjudication by the Expert Committee, fromInnovative Medical Devices & Intelligent Manufacturing, Innovative Pharmaceuticals & Biologics, Digital Health & Healthcare Services, Healthcare Commerce & Supply Chain ServicesSelect the top 100 most valuable innovative enterprises in each of the four major sectors. In addition to valuation, candidate companies will be further evaluated on their growth and annual performance across four primary indicators—human resources, knowledge resources, key partner resources, and market performance—comprising a total of 17 secondary indicators.
I. Top 100 List of Innovative Medical Devices and Intelligent Manufacturing
Scope of Call for Submissions:
The scope primarily covers R&D and manufacturing enterprises in the fields of medical devices, medical consumables, and in vitro diagnostics (IVD), as well as companies that independently develop innovative medical devices and intelligent manufacturing products supported by digital technologies (such as cloud computing, big data, and artificial intelligence). This includes, but is not limited to, enterprises in the following areas: high-value consumables (cardiovascular, orthopedic, ophthalmic, dental, neurological, blood purification, non-vascular intervention, etc.); low-value consumables (medical hygiene materials and dressings, anesthesia consumables, disinfection consumables, injection and puncture consumables, etc.); medical equipment (imaging, patient monitoring, radiotherapy, physical and chemical analysis, dialysis, laser, surgical, rehabilitation, etc.); home-use medical devices (blood pressure monitors, blood glucose meters, ventilators, oxygen concentrators, massagers, etc.); AI-enabled medical devices (smart wearable devices, AI-based medical imaging, etc.); medical robots (surgical robots, rehabilitation robots, etc.); and in vitro diagnostics (biochemical diagnostics, immunoassays, molecular diagnostics, POCT, microbiological diagnostics, hematology diagnostics, etc.).
Eligibility Criteria:
A. Non-listed companies in the fields of innovative medical devices and intelligent manufacturing;
B. The place of registration or principal place of business is in China (including Mainland China, Hong Kong, Macao, and Taiwan);
C. Still in operation as of the selection date, with the capacity for continued operations;
D. At least secured angel-round financing (if there is no external financing, detailed valuation assessment materials must be provided as required);
E. Possesses significant innovations in products, technologies, materials, business models, etc.;
F. The enterprise has a good reputation, with no major violations or penalties in the past three years.
II. Top 100 Innovative Pharmaceuticals and Biological Products
Scope of Call for Submissions:
Primarily covering pharmaceutical companies engaged in R&D, production, innovative drugs and biologics, or providing innovative therapies, as well as enterprises that independently conduct R&D of innovative pharmaceuticals and biologics supported by digital technologies (such as cloud computing, big data, and artificial intelligence). This includes, but is not limited to, companies in fields related to biological drugs and biologics for prevention, treatment, diagnosis, and healthcare (e.g., antibodies, vaccines, blood products, cell therapy, gene therapy), chemical drugs (e.g., generics, innovative drugs), and traditional Chinese medicine (e.g., traditional Chinese medicine, innovative TCM).
Eligibility Requirements:
A. Non-listed companies in innovative pharmaceuticals and biologics;
B. The place of registration or primary operations is in China (including mainland China and the Hong Kong, Macao, and Taiwan regions);
C. Still operational as of the evaluation date, with the capacity for continued operations;
D. Have secured at least angel-round financing (if there is no external financing, detailed valuation assessment materials must be provided as required);
E. Possesses significant innovations in products, technologies, therapies, or applications;
F. The enterprise has a good reputation, with no major violations or penalties within the past three years.
III. Top 100 Digital Healthcare and Health Services List
Scope of Call for Submissions:
It primarily covers enterprises that directly provide patients with services such as diagnosis, treatment, testing, rehabilitation, health consultation, and online education, as well as those that empower patients in disease prevention, diagnosis, treatment, rehabilitation, and health management through digital technologies (such as cloud computing, big data, and artificial intelligence). This includes, but is not limited to, general hospitals, specialized hospitals, standalone hospitals, hospital chains, and clinics in the non-public medical sector (covering both serious medical care and consumer healthcare); physician groups; internet hospitals; mobile health/telemedicine platforms; patient consultation service platforms; digital therapeutics (for chronic diseases, neurological disorders, cognitive behavioral therapy, etc.); pharmacies and retail terminals; IVD and precision diagnostics services; and third-party service providers for testing, imaging, and health check-ups.
Eligibility Criteria:
A. Non-listed companies in the digital healthcare and health services sector;
B. Place of registration or principal place of business is in China (including the mainland, Hong Kong, Macau, and Taiwan);
C. Must be operational as of the selection date and possess the capability for sustained operations;
D. Must have secured at least angel-round financing (if there is no external financing, detailed valuation assessment materials must be provided as required);
E. Possesses significant innovations in products, services, business models, and other aspects;
F. The enterprise has a good reputation, with no major violations or penalties in the past three years.
IV. Top 100 Healthcare Commerce and Supply Chain Services List
Scope of Call for Submissions:
Companies that primarily provide commercial and supply chain services to B-end (business), H-end (hospital/healthcare institution), and G-end (government) clients, such as hospitals, enterprises, and other medical institutions; as well as companies that, supported by digital technologies (cloud computing, big data, artificial intelligence, etc.), provide business process digital transformation and R&D/marketing/distribution digital upgrade services to B-end/H-end/G-end clients. This includes, but is not limited to, companies in related fields such as pharmaceutical and medical device CROs/CMOs/CDMOs/CSOs; life science tools and services including upstream raw materials, consumables, and equipment for pharmaceuticals and medical devices; digital drug R&D services; innovative channel and marketing services; innovative payment solutions; innovative cold chain and logistics services; medical insurance and financial services; third-party sterilization services; smart hospital construction services; and medical IoT services.
Eligibility Requirements:
A. Non-listed companies in the healthcare commercialization and supply chain services sector;
B. The place of registration or primary operations is in China (including the mainland, Hong Kong, Macao, and Taiwan);
C. Operational up to the evaluation date and capable of sustained operations;
D. Have secured at least angel-round financing (if there is no external financing, detailed valuation assessment materials must be provided as required);
E. Possesses significant innovations in products, services, business models, and other aspects;
F. The enterprise has a good reputation, with no major violations or penalties within the past three years.
As a backbone of China’s economic development, listed companies’ innovation capability is not only the core engine for corporate growth but also holds significant practical importance for national innovation strategies and industrial upgrading. This ranking is based onAnnual Report Data of Listed Companies for the Current Yearas the basis, supplement research on listed companies inInnovation Input, Innovation Output, Innovation Efficiency, and Innovation ActivitiesSelected based on over 30 relevant indicators across four dimensions, combined with VCBeat’s assessment methodology for analyzing innovation trends and market potential in the sectors where listed companies operate.
Selection Criteria:
A. Healthcare sector companies listed on the Hong Kong Stock Exchange and A-share market;
B. As of the publication date, enterprises that have consecutively disclosed their annual reports for two years (including the annual report for the year preceding the publication year), or enterprises that, although not having consecutively disclosed annual reports for two years, are able to provide data for all indicators in the Innovation Assessment Model;
C. The place of registration or principal place of business is in China (including mainland China, Hong Kong, Macau, and Taiwan);
D. The entity must be operational as of the selection date and possess the capability for sustained operations;
E. Significant innovations in products, services, business models, etc.;
F. The enterprise has a good reputation, with no major violations or penalties in the past three years.
Note: Listed companies are not required to register independently for this ranking.
Annual Healthcare Direct Investment Fund of Funds
Submission Requirements:
A. Various fund of funds that have designated healthcare as a primary or key investment focus;
B. The fund exerts significant influence and driving force in promoting the development of the medical and health industry;
C. The fund has successful investment cases in the healthcare sector;
D. The fund’s cooperative sub-funds possess brand influence in the healthcare sector;
E. The healthcare enterprises within the investment ecosystem demonstrate robust development and maintain a strong brand reputation;
F. The fund shall establish a direct-investment parent fund to make equity investments directly in non-listed enterprises in the healthcare sector;
G. This award primarily evaluates the performance of participating funds in making direct investments in non-listed companies within the healthcare sector during the review year.
Evaluation Dimensions:
Fund Management, Investment Activities, Exit Performance, and Annual Direct Investment Performance in the Healthcare Sector.
Top Annual Innovative Medical Device Investment Firms
Submission Requirements:
A. Institutional investors that focus on investing in the medical device sector (no restrictions on investment stage);
B. The institution possesses brand influence in the medical device sector;
C. The institution has successful investment cases in the field of medical devices;
D. The medical device companies invested in by the institution demonstrate strong development and a favorable brand reputation.
Evaluation Dimensions:
Fundraising and Fund Management; Annual Investment, Exit, and Post-Investment Value-Added Services in the Medical Device Sector.
Annual Innovative Pharmaceutical Investment Institution
Call for Submissions:
A. Institutional investors focusing on investments in the biopharmaceutical sector (investment stage is not limited);
B. The institution possesses brand influence in the biopharmaceutical sector;
C. The institution has successful investment cases in the biopharmaceutical field;
D. The biopharmaceutical companies invested in by the institution demonstrate strong development and maintain a favorable brand reputation.
Evaluation Dimensions:
Fundraising and Fund Management Status; Annual Investment, Exit, and Post-Investment Value-Added Activities in the Biopharmaceutical Sector.
Annual Digital Health Investment Firm
Call for Submissions:
A. Institutional investors or those focusing on investments in the digital healthcare sector (investment stage is not limited);
B. The institution has brand influence in the field of digital health;
C. The institution has successful investment cases in the field of digital health;
D. The digital health companies invested in by the institution have demonstrated strong development and maintained a favorable brand reputation.
Evaluation Dimensions:
Fundraising and Fund Management; Annual Investment, Exit, and Post-Investment Value-Added Services in the Digital Health Sector.
Annual Healthcare Investment Institution
Submission Requirements:
A. Institutional investors should focus on investing in the healthcare services sector (with no restrictions on investment stage);
B. The institution has brand influence in the field of medical services;
C. The institution has successful investment cases in the healthcare services sector;
D. The healthcare service companies invested in by the institution demonstrate strong development and a favorable brand reputation.
Evaluation Dimensions:
Fundraising and Fund Management Status; Annual Investment, Exit, and Post-Investment Value-Added Services in the Healthcare Sector.
Annual Healthcare Strategic Investment Institution
Submission Requirements:
A. Strategic investment institutions that invest in or focus on the healthcare sector;
B. The institution has brand influence in the healthcare sector;
C. The institution has successful investment cases in the healthcare sector;
D. The institution serves healthcare enterprises with strong development and favorable brand reputation.
Evaluation Dimensions:
Fundraising and Fund Management Status; Annual Investment, Exit, and Post-Investment Value-Add Activities in the Healthcare Sector.
Annual Post-Investment Empowerment Service Provider for Healthcare
Call for Submissions:
A. Institutional investors may focus their investments on the healthcare and medical sector;
B. The institution has brand influence in the healthcare sector;
C. The institution has successful investment cases in the healthcare sector;
D. The healthcare and medical enterprises invested in by the institution demonstrate robust development and maintain a strong brand reputation;
E. This award primarily evaluates the value-added services provided by participating institutions to their portfolio healthcare projects during the review year. Applicants are required to submit information on the methods of value-added services, the status of service delivery, and annual growth metrics of the supported projects.
Evaluation Dimensions:
Fundraising and Fund Management, Investment Activities, and Annual Performance in Empowering Services within the Healthcare Sector.
Annual Cross-Border Healthcare and Emerging Investment Institutions
Submission Requirements:
A. Investment institutions that invest in or focus on healthcare (with no restrictions on investment sectors or stages);
B. Newly established institutions must have been founded within the past three years (i.e., after 2021);
C. Cross-sector investment institutions must have made their first investment in the healthcare sector within the past three years;
D. The institution has successful investment cases in the healthcare sector;
E. The healthcare and medical enterprises invested in by the institution demonstrate robust development and maintain a strong brand reputation.
Evaluation Dimensions:
Fundraising and Fund Management Status; Annual Investment, Exit, and Post-Investment Value-Added Services in the Healthcare Sector.
Annual Healthcare Financial Advisory Firm
Call for Submissions:
A. Financial advisory firms serving the healthcare sector;
B. The institution has brand influence in the healthcare sector;
C. The institution has successful service cases in the healthcare field;
D. The enterprises in the healthcare sector served by the institution demonstrate robust development and maintain a strong brand reputation.
Evaluation Dimensions:
Annual Overview of Service Cases, Sector Research, and Empowerment Initiatives in the Healthcare Industry.
Annual Leading Enterprise
Call for Submissions:
A. Listed companies in the healthcare sector (regardless of listing location);
B. The company has had no major regulatory violations and has operated normally over the past five years;
C. Possesses achievements in technological innovation, product innovation, and business model innovation that are ahead of industry peers;
D. Possesses a strong social reputation and brand influence.
Evaluation Dimensions:
Annual corporate performance in value growth, innovation breakthroughs, and social responsibility.
Annual Outstanding Enterprise
Call for Submissions:
A. Non-listed companies in the healthcare sector, established within the past 10 years with normal operations, and valued at RMB 6.5 billion or above;
B. The enterprise is an industry leader, with active market performance and significant industrial influence;
C. The company has significant advantages in services, technology, and operational models;
D. The enterprise possesses a strong social image and the capability to lead industry development trends.
Evaluation Dimensions:
Corporate annual performance in value growth, innovation breakthroughs, and social responsibility.
Innovative Enterprise of the Year
Submission Requirements:
A. Non-listed companies in the healthcare sector with normal operations, valued between RMB 1.5 billion and RMB 6.5 billion;
B. The company is a leader in its sector, with strong market performance;
D. The enterprise’s financing stage is post-Series A;
C. The enterprise has achieved significant innovative breakthroughs in areas such as services, technology, and operational models.
Evaluation Dimensions:
Corporate Annual Performance in Value Growth, Innovation Breakthroughs, and Social Responsibility.
Annual High-Potential Enterprise
Call for Submissions:
A. Non-listed companies in the healthcare sector, established within the past three years with normal operations, and valued at less than RMB 1.5 billion;
B. The company's financing stage is Series A or earlier;
C. The enterprise possesses business model innovation, technological innovation, and product innovation.
Evaluation Dimensions:
Annual Value Growth and Innovation Breakthrough Performance of the Enterprise.
*BestPharmaceutical CRO with Highest Customer Satisfaction, Medical Device CRO with Best Customer Satisfaction,Best Customer Satisfaction Pharmaceutical CDMO,Best Customer-Satisfaction Medical Device CDMOFour awards will be independently selected through industry research. The research will be conducted progressively in accordance with the selection timeline, and no additional application is required.Stay tuned.。
Annual Benchmark Biopharmaceutical Industrial Park
Submission Requirements:
A. Industrial parks that demonstrate innovation in the development of industrial technology systems, enhancement of scientific and technological innovation capabilities, construction of industrial chains, exploration of innovative service models, cultivation of specialized market segments, and establishment of financial systems;
B. Primarily serving biopharmaceutical enterprises.
Evaluation Dimensions:
The park's capabilities in scientific and technological innovation, industrial agglomeration, financial services, and policy support.
Annual Benchmark Industrial Park for Medical Devices
Call for Submissions:
A. Industrial parks that demonstrate innovation in the construction of industrial technology systems, enhancement of scientific and technological innovation capabilities, development of industrial chains, exploration of innovative service models, cultivation of specialized market segments, and establishment of financial systems;
B. Focus on serving medical device companies.
Evaluation Dimensions:
The park's capabilities in technological innovation, agglomeration, financial services, and policy support.
Annual Benchmark Industrial Park for Digital Health
Call for Submissions:
A. Industrial parks that demonstrate innovation in the construction of industrial technology systems, scientific and technological innovation capabilities, industrial chains, exploration of innovative service models, cultivation of niche sectors, and financial systems;
B. Primarily serving digital health enterprises.
Evaluation Dimensions:
The park’s capabilities in technological innovation, talent and enterprise aggregation, financial services, and policy support.
Annual Healthcare Leader Entrepreneur (Nomination Category)
Nominator Requirements:
A. Employed by a publicly listed healthcare company;
B. Being a member of the core executive team of affiliated enterprises, holding key leadership positions such as Chairman or CEO;
C. Entrepreneurs possess outstanding capabilities in corporate management, financial returns, and innovative insights into the medical industry;
D. The entrepreneur possesses social recognition and industry influence, leading the innovation process and trends within the industry;
E. Entrepreneurs maintain a positive public image with no negative publicity, and proactively assume—while leading their companies to assume—social responsibility.
Employer Requirements:
A. The employing enterprise possesses brand influence in the healthcare sector;
B. The business areas of the candidate's employer must fall within the scope of innovative pharmaceuticals, innovative medical devices, digital health and healthcare services, as well as healthcare commerce and supply chain services;
C. The employing company must be a publicly listed enterprise registered in China (limited to A-shares and Hong Kong stocks), with an average daily total market capitalization exceeding RMB 50 billion in 2023;
D. The company demonstrated strong operational performance, stable profitability, and steady revenue growth during the evaluation year;
E. The employing company must be included in the 2024 VBEF List · Innovation Ranking of Listed Companies.
Evaluation Dimensions:
Individual innovation capability, industry influence, corporate leadership, social recognition, company size, and financial performance.
Note：The AwardItemParticipation in the ElectionMethod: "LiftRecommendedRecommendation,” no self-declaration required.
Annual Outstanding Entrepreneur in Healthcare (Application Category)
Selection Criteria:
A. Serving as a founder, co-founder, CEO, or other key leadership roles in publicly listed companies, unicorn companies, and innovative enterprises;
B. The enterprise has no major violations and operates normally;
C. The entrepreneur personally engages in entrepreneurial and innovative practices, driving the continuous development of the enterprise;
D. Entrepreneurs maintain a positive public image and proactively assume social responsibility.
Evaluation Dimensions:
Individual innovation capability, industry influence, corporate leadership, company size, and financial performance.
Annual Young Healthcare Entrepreneur(Declaration Category)
Selection Criteria:
A. Serving in key leadership roles such as founder, co-founder, or CEO at innovative enterprises;
B. Age not exceeding 45 years (including 45 years);
C. The enterprise has no major violations and operates normally;
D. The entrepreneur personally engages in entrepreneurial and innovative practices, driving the continuous development of the enterprise;
E. Entrepreneurs maintain a positive public image and proactively assume social responsibility.
Evaluation Dimensions:
Individual Innovation Capability, Industry Influence, and Corporate Leadership.
Annual Healthcare Investment Leader (Nomination Category)
Nominee Requirements:
A. Employed at an investment institution focusing on the primary market for healthcare and medical services;
B. Be a member of the core management team of your affiliated institution, with responsibility for overseeing investments in the healthcare sector;
C. Led no fewer than 10 representative investment cases and achieved no fewer than 5 representative exit cases in the medical and healthcare sector;
D. Led five or more investments in the primary healthcare market in 2023, and received no fewer than three mainstream media awards for equity investors (not limited to the healthcare sector);
E. Possess outstanding equity investment capabilities, keen insights into innovation in the healthcare industry, and significant industry recognition and influence;
F. During the review year, the target company demonstrated sound operational performance and was in a growth phase.
Employer Requirements:
A. The employing institution possesses brand influence in the healthcare sector and is required to invest in, or focus its investments on, China’s healthcare industry, with areas of interest including innovative pharmaceuticals, innovative medical devices, digital health and health services, as well as healthcare commerce and supply chains.
B. Current employer; manages funds with a scale of no less than RMB 10 billion, which are eligible to invest in China’s healthcare industry.
C. The employing institution has successful investment cases in the healthcare sector, with a cumulative total of no fewer than 50 healthcare projects invested.
D. The employing institution must have been selected for at least two awards in the Institutional Category of the 2024 VBEF Innovation Awards.
Evaluation Dimensions:
Annual investment and exit performance, institutional management and operational capabilities, equity investment capabilities, industry insights, industry influence, and the scale and growth potential of portfolio companies.
Note: The nomination process for this award is by “nomination and recommendation” only; self-nomination is not required.
Annual Outstanding Investor in Healthcare (Nomination Category)
Eligibility Requirements:
A. Working at a primary market investment institution in the healthcare sector;
B. Head of the healthcare investment team at his/her institution;
C. Led representative investment cases during personal investment career (limited to the healthcare and medical sector);
D. Led three or more investments in the primary healthcare market in 2023;
E. Possess excellent equity investment capabilities, insightful understanding of innovation in the healthcare industry, and high industry recognition and influence;
F. During the review year, the invested company demonstrated sound operational performance and was in a growth phase.
Evaluation Dimensions:
Annual investment and exit performance, team management capabilities, equity investment expertise, industry insight, industry influence, and the scale and growth potential of portfolio companies.
Annual Young Healthcare Investor(Declaration Category)
Eligibility Requirements:
A. Working at a primary market investment institution in the healthcare sector;
B. Age not exceeding 45 years (inclusive);
C. Led representative investment cases during personal investment career (limited to the healthcare sector);
D. Led three or more investments in the primary healthcare market during 2022–2023;
E. Possess excellent equity investment capabilities and keen insights into innovation in the healthcare industry;
F. During the review year, the invested company demonstrated sound operational performance and was in a growth phase.
Evaluation Dimensions:
Annual investment and exit performance, equity investment capability, industry insight, and the scale and growth potential of portfolio companies.
*Excellent Pharmaceutical and Medical Device Supply Chain Products, Most Procurement-Worthy Supply Chain Products, Best Technical Service Supply Chain ProductsThree awards will be independently selected through industry research. The research will be conducted progressively in accordance with the selection schedule, and no additional application is required.Stay tuned。
I. Self-Declaration and Third-Party Recommendation:
December 08, 2023 – March 31, 2024
II. Information Review and First-Round Evaluation:
April 1, 2024 – April 14, 2024
III. Cross-Review by the Expert Panel:
April 15, 2024 – April 28, 2024
IV. Final Review and Approval, Report Preparation:
April 29, 2024 – May 5, 2024
V. Selection, Announcement, and Award Ceremony:
May 2024 · On-Site at the 2024 Future Healthcare Ecosystem Expo
Note: The release schedule and call-for-entries timeline will be adjusted based on the dates of the 2024 Future Healthcare Ecosystem Expo. All participating entities will be notified via email and SMS of any changes to the submission period and the confirmed release dates.
Application Method
I. Submission via Official Website:Each applicant entity may proceed to[Official Website of the Ranking] - [Submission Guidelines] - [Download Materials]Download the application materials from the interface, prepare the relevant documents based on the application materials, and then via the [Registration Channel] Fill in the declaration information online.
(Scan the QR code to visit the official ranking website)
Official Website Link: http://vb100.vcbeat.top/list#/
II. Online Submission:Each applicant entity may also complete the application process by directly filling out the required information online through the designated submission portal.
【Institutional】
https://vb100.mike-x.com/Qir1y
【Corporate】
https://vb100.mike-x.com/tCv7N
[Park-Type]
https://vb100.mike-x.com/SsCk8
Note:
1. To prevent omissions in submission materials, facilitate data analysis, and enable timely notifications to enterprises, this selection process accepts only online submissions; Word application forms will not be accepted. Thank you for your understanding!
2. The submission page does not support saving. It is recommended to complete the Word application form first, then copy and paste its contents into the submission portal, and ensure that the materials are successfully submitted on your own.
Declaration Consultation
Registration Consultation
13364027163
Application Consultation
15696132719
Finally, we look forward to greater industry participation in jointly producing the Growth Analysis Report of the Top 100 Future Healthcare Companies and selecting winners for the Value Domain Awards. Through systematic review and analysis, we aim to ensure that selection data flows seamlessly, evaluation logic is transparent, and results are easily interpretable.
Every year, VB100 releases the “Top 100 Enterprises Growth Analysis Report” based on that year’s Future Healthcare 100 rankings. The report provides a comprehensive analysis of relevant data for companies on the main list, summarizes patterns of corporate growth and trends in industrial evolution, and offers reference insights for healthcare enterprises and entrepreneurs. The Innovative Case Studies section of the report is open to submissions from all companies listed in the current edition. We aim to identify the most representative innovative and high-potential enterprises in the healthcare industry, conducting in-depth research on their business, product, financing, and valuation data to observe the growth trajectories of healthcare companies and the direction of industry transformation from a more authentic and comprehensive perspective. Submissions for case study inclusion are being accepted concurrently with the 2024 VBEF award applications. Participating organizations interested in having their cases featured may complete the relevant information at the end of the application link.
Each year, VCBeat’s VB100 initiative conducts multi-dimensional, comprehensive insights and explorations through investor interviews, journalist interviews, and industry report analyses. Using capital attention as the primary benchmark, supplemented by media focus, annual performance data热度 of healthcare enterprises, and future industry prosperity indicators, it reviews over 60 sub-sectors across five major tracks—medical devices, biopharmaceuticals, digital health, medical services, and others—to identify the most representative value segments of the year and select the most representative and high-growth innovative companies within each segment. The 2024 VBEF Innovation Awards · Value Segment Award – Sub-sector Value Research and Selection is currently underway; investment institutions and enterprises are welcome to recommend hot sectors and tracks.
2024 Future Healthcare Ecosystem Expo
The Top 100 Future Healthcare Conference, an annual flagship event under VCBeat, aims to gather core industry forces, drive innovation and transformation in the healthcare sector, build a communication and matchmaking platform for the entire medical and health industry chain, and accelerate the rapid development of the most high-growth-potential sectors and enterprises.
Established in 2016, the Future Healthcare Top 100 Conference has successfully held seven editions to date. It has featured over 1,500 speakers from China and abroad, including academicians, scientists, and renowned entrepreneurs. Nearly 8,300 companies have participated, gathering the Top 100 enterprises in China’s healthcare innovation sector, as well as Fortune Global 500 companies, multinational corporations, and listed companies. More than 1,200 angel investors, venture capital (VC) firms, private equity (PE) firms, investment banks, strategic investors, and securities firms consider it a must-attend annual event. Each year, cumulative media exposure across healthcare, finance, and general media outlets exceeds 20 million impressions, serving as a direct platform for media visibility for companies in the healthcare innovation sector. For seven consecutive years, it has released the highly authoritative Future Healthcare Top 100 List. Concurrently, it hosts industry-specific forums, innovation exhibitions, and government-enterprise exchange meetings. As the largest and most information-rich summit integrating scientific innovation, industry, and capital in China’s healthcare innovation sector, it sets the tone for development and investment trends in the field for the current year and the foreseeable future.
In 2024, the Future Healthcare Top 100 Conference was fully upgraded to the VBEF Future Healthcare Ecosystem ExpoCentered on the needs of enterprises in the healthcare sector, it serves the entire industry spanning biopharmaceuticals, medical devices, digital health, healthcare services, and healthcare commerce and supply chain services, with a focus on global innovations in the healthcare industry—new technologies, new models, new practices, and new ecosystems.
Find 100 Product Launch Event
The Find 100 Product Launch is a featured product unveiling event first introduced at the 2024 Future Medical Ecosystem Expo. It aims to showcase innovative healthcare products (solutions) that demonstrate technological advancement, meet clinical medical needs, and exhibit outstanding industry-leading impact. The exhibition will focus on innovative biologics and biological products, high-end intelligent manufacturing and medical devices, digital innovation technology platforms, and supply chain empowerment services/solutions. It will highlight the flagship or latest products (solutions) from over 100 companies, providing exclusive launch segments to propel these new offerings onto a broader stage. At the 2024 Future Medical Ecosystem Expo, the Find 100 Product Launch will feature dedicated areas including a product launch stage, a textual product display zone, and an interactive communication area. Leveraging the attendee base of the 2024 Future Medical Innovation Ecosystem Expo, it seeks to create a platform for showcasing and trading frontier research and application achievements in healthcare, thereby empowering the brand growth of healthcare products.
Call for Consultations
13364027163
Review of Past Selections
Click to visit the official awards website for more details.